BHVN:NYE-Biohaven Pharmaceutical Holding Company Ltd (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 88.36

Change

+1.33 (+1.53)%

Market Cap

USD 5.22B

Volume

0.35M

Average Target Price

USD 88.50 (+0.16%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.60 (+0.89%)

USD155.67B 27.30 2.61
ADCT ADC Therapeutics SA

+0.24 (+0.67%)

USD2.91B -99,999.99 N/A
ZYME Zymeworks Inc

+0.59 (+1.08%)

USD2.49B 300.20 N/A
MYOV Myovant Sciences Ltd

-0.87 (-3.56%)

USD2.21B N/A N/A
RCUS Arcus Biosciences, Inc

+1.03 (+3.68%)

USD1.82B N/A N/A
CVM CEL-SCI Corporation

+0.10 (+0.84%)

USD0.46B N/A N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
RFL Rafael Holdings, Inc

+0.58 (+2.60%)

USD0.35B N/A N/A
IBIO iBio, Inc

-0.03 (-1.97%)

USD0.28B N/A N/A
CRMD CorMedix Inc

-0.05 (-0.58%)

USD0.27B N/A N/A

ETFs Containing BHVN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 62.31% 73% C 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.31% 73% C 94% A
Trailing 12 Months  
Capital Gain 61.09% 73% C 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.09% 73% C 93% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 25.03% N/A N/A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.03% N/A N/A 93% A
Risk Return Profile  
Volatility (Standard Deviation) 34.77% N/A N/A 16% F
Risk Adjusted Return 71.98% N/A N/A 81% B-
Market Capitalization 5.22B 97% A+ 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 31.82 11% F 2% F
Price / Cash Flow Ratio -13.82 69% D+ 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -188.51% 32% F 1% F
Return on Assets -62.41% 29% F 1% F
Debt to Equity Ratio -3,337.24% 100% A+ 99% A+
Technical Ratios  
Short Ratio 12.43 14% F 3% F
Short Percent 16.36% 8% F 29% F
Beta 1.11 73% C 47% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector